Labcorp(US:LH)2025-10-28 10:55Financial Performance - Labcorp reported third-quarter 2025 revenue of $3.56 billion, an increase of 8.6% compared to $3.28 billion in Q3 2024[4]. - Diluted EPS for Q3 2025 was $3.12, up from $2.00 in Q3 2024, while adjusted EPS rose to $4.18 from $3.50, reflecting a 19.4% increase[4]. - Revenues for Q3 2025 reached $3,563.5 million, a 8.6% increase from $3,282.0 million in Q3 2024[29]. - Gross profit for Q3 2025 was $1,025.1 million, up 13.3% from $904.4 million in Q3 2024[29]. - Operating income for the nine months ended September 30, 2025, was $1,117.1 million, a 28.4% increase compared to $870.2 million for the same period in 2024[29]. - Net earnings attributable to Labcorp Holdings Inc. for Q3 2025 were $261.1 million, representing a 54.3% increase from $169.3 million in Q3 2024[29]. - Basic earnings per share for Q3 2025 were $3.14, compared to $2.02 in Q3 2024, reflecting a 55.4% increase[29]. - Net earnings for the three months ended September 30, 2025, were $261.5 million, a 54.1% increase from $169.6 million in the same period of 2024[33]. - Revenues from Diagnostics Laboratories reached $2,769.6 million for the three months ended September 30, 2025, up 8.5% from $2,553.5 million in 2024[36]. - Adjusted operating income for the consolidated segment was $513.3 million for the three months ended September 30, 2025, compared to $441.1 million in 2024, reflecting a 16.4% increase[39]. - The adjusted operating margin improved to 14.4% for the three months ended September 30, 2025, compared to 13.4% in the same period of 2024[39]. - Adjusted net income for the nine months ended September 30, 2025, was $1,038.3 million, up from $939.9 million in 2024, indicating a 10.5% increase[39]. Cash Flow and Investments - Labcorp's operating cash flow for Q3 2025 was $387.2 million, compared to $277.3 million in Q3 2024, indicating strong cash generation[10]. - Net cash provided by operating activities was $387.2 million for the three months ended September 30, 2025, compared to $277.3 million in 2024, representing a 39.7% increase[33]. - Capital expenditures for the three months ended September 30, 2025, were $106.7 million, a decrease from $115.8 million in the same period of 2024[33]. - The company reported a net cash used for investing activities of $374.0 million for the three months ended September 30, 2025, compared to $579.1 million in 2024[33]. Guidance and Future Outlook - The company updated its full-year revenue guidance to a growth range of 7.4% to 8.0%, with the midpoint lowered by 40 basis points due to currency and acquisition timing[4]. - Free cash flow for the year is now projected to be between $1.17 billion and $1.29 billion, with the midpoint raised by $25 million[4]. - The company anticipates future growth opportunities through strategic acquisitions and partnerships, although specific financial guidance for 2025 remains subject to various uncertainties[24][25]. Debt and Financial Health - Labcorp's total debt at the end of the quarter was $5.58 billion, with cash and cash equivalents of $598 million[11]. - Total assets as of September 30, 2025, were $18,261.6 million, slightly down from $18,379.0 million at the end of 2024[31]. - Total liabilities decreased to $9,548.6 million from $10,312.5 million at the end of 2024, indicating improved financial health[31]. - Cash and cash equivalents decreased to $598.1 million from $1,518.7 million at the end of 2024, highlighting a significant reduction in liquidity[31]. Strategic Initiatives - Labcorp signed several strategic agreements with health systems and regional laboratories, enhancing its partnerships in the healthcare sector[5]. - The company advanced its oncology and genetic testing portfolio, including the expansion of OmniSeq® INSIGHT and the introduction of new Alzheimer's tests[6]. - The backlog for Biopharma Laboratory Services increased by 5.4% year-over-year, with a total backlog of $8.58 billion[15]. Workforce and Operations - Labcorp's workforce consists of nearly 70,000 employees serving clients in approximately 100 countries, supporting 75% of new drugs approved by the FDA in 2024[23].